

LPGENFSHIN007 FISH Probe List

Copy of version 18.0 (approved and current)

Last Approval or
Periodic Review Completed 01/12/2025

Next Periodic Review
Needed On or Before 01/12/2027

Effective Date 01/12/2025

Uncontrolled Copy printed on 22/04/2026 8:59

Organization LabPLUS – Te Toka Tumai District

Description

UPDATED LIST OF FISH PROBES (BY DISORDER) THAT ARE ROUTINELY USED IN THE DEPARTMENT

Comments for version 18.0

Reviewed by section leaders and Jason Tseung. TATs simplified, probe specific location, colour and manufacturer details removed

Approval and Periodic Review Signatures

Type	Description	Date	Version	Performed By	Notes
Approval	Approval	01/12/2025	18.0	Emilie Parkes (10157)	
Approval	Approver	27/11/2025	18.0	Sajayan Joseph (36654)	
Approval	Approver	30/01/2025	17.0	Sajayan Joseph (36654)	
Approval	Approval	28/01/2025	17.0	Megan Crowley (21874)	
Periodic review	Designated Reviewer	24/01/2025	16.0	Lisa Duffy (124082)	Updated header
Approval	Approval	03/03/2023	16.0	Megan Crowley (21874)	
Approval	Approver	03/03/2023	16.0	Sajayan Joseph (36654)	
Approval	Approver	10/11/2021	15.0	Sajayan Joseph (36654)	
Approval	Approval	11/10/2021	15.0	Megan Crowley	
Periodic review	Designated Reviewer	20/04/2021	14.0	Lisa Duffy	
Approval	DG Technical Head	01/10/2018	14.0	Mark Greenslade	
Approval	Approval	14/09/2018	14.0	Karen Claxton	
Approval	DG Technical Head	04/10/2016	13.0	Alice George	
Approval	Section leader	28/09/2016	13.0	Liangtao Zhang	
Approval	Approval	28/09/2016	13.0	Rachel O'Connor	

Approval Captured outside MediaLab	Lab Director	13/11/2014	12.0	Lisa Duffy	Recorded on 24/02/2015 by Karen Rogers (976415) when document added to Document Control
Periodic review Captured outside MediaLab	Designated Reviewer	13/11/2014	12.0	Lisa Duffy	Recorded on 24/02/2015 by Karen Rogers (976415) when document added to Document Control

Approvals and periodic reviews that occurred before this document was added to Document Control may not be listed.

Prior History

LISA DUFFY (13/11/2014): Header and Footer reformatted so that it is visible when printed. Corrected; FISH not ADMINISTRATION and;

LISA DUFFY (11/11/2014): Header and footer corrected and document updated;

LISA DUFFY (11/02/2014): Updated with version that has header and footer;

LISA DUFFY (07/02/2014): Updated and revised;

LISA DUFFY (20/11/2013): Details revised and updated from handwritten amendments.;

JESSICA DEPETRO (16/11/2012): Updated several probes where supplier has changed.;

JESSICA DEPETRO (05/11/2012): Added additional probes, made minor corrections to typos, updated header and footer.;

LIANGTAO ZHANG (10/08/2011): Revised;

LIANGTAO ZHANG (07/03/2011): Revised to reflect current practice;

LIANGTAO ZHANG (05/03/2009): Revised to reflect current practice;

FERN ASHTON (05/02/2007): no changes;

Version History

Version	Status	Type	Date Added	Date Effective	Date Retired
18.0	Approved and Current	Major revision	27/11/2025	01/12/2025	Indefinite
17.0	Retired	Major revision	24/01/2025	30/01/2025	01/12/2025
16.0	Retired	Major revision	01/03/2023	03/03/2023	30/01/2025
15.0	Retired	Major revision	08/10/2021	10/11/2021	03/03/2023
14.0	Retired	Major revision	14/09/2018	30/09/2018	10/11/2021
13.0	Retired	Major revision	13/05/2016	03/10/2016	30/09/2018
12.0	Retired	First version in Document Control	24/02/2015	13/11/2014	03/10/2016

FISH PROBE LIST

Diagnostic Genetics

PRENATAL/PERINATAL FISH TESTING	TAT(DAYS)*	Probe Location	Probe	NOTES
ANEUSCREEN (AF,CVS AND POCs)- All abnormal results (except NIPT)	2	Xp11.1-q11.1/Yp11.1-q11.1/	CEP X/Y/18	² Not mapped to the human genome.
		18p11.1-q11.1		² Not mapped to the human genome.
		13q14/21q22.1-q22.2		[chr13:48735473-49158073 /chr21:39439949-39439949]
DIGEORGE SYNDROME/ VCFS / CATCH22	2	22q11.21/22q11.21-q11.22	HIRA/TBX1, CRKL, MAPK1 DiGeorge probe	[ch22:19068456-19932689/21096895-21454102/21096895-21454102]
		22q11.2/22q13	HIRA/ARSA (By clinical request only)	[chr22:19289001-19405903] ¹
EARLY PREGNANCY LOSS/REC. MISC. (unvalidated)	2	16p11.1-q11.1	CEP16 (By clinical request only)	² Not mapped to the human genome.
		22q11.1-11.21	CEP22 (By clinical request only)	
MOLAR PREGNANCY AND ANEUPLOIDY (FFPE SAMPLES)	18	18p11.1-q11.1/Xp10-q10/Yq12	CEP18/ X/Yqh	² Not mapped to the human genome.
		13q12.11/21q22.13-q22.2	13 RB1 /21 DSCR4 unique sequence	[chr13:48735473-49158073 /chr21:39439949-39439949]
NIPT CONFIRMATIONS (not validated)	2	Variable	By clinical request only	
POSTNATAL FISH TESTING		Probe Location	Probe	
CRI DU CHAT (5p15.2) SYNDROME	7*	5q31/5p15.2	EGR1/D5S23,D5S721	[chr5:9450109 – 10011407] ¹
		5q33-q34/5p15.2	CSF1R/D5S23, D5S721 (By clinical request only)	[chr5:149272612-149594994 /chr5:9397109-9397109]
CAT EYE SYNDROME	7*	22q11.1-11.21	CEP22	
DIGEORGE SYNDROME/ VCFS / CATCH22	2	22q11.21/22q11.21-q11.22	HIRA/TBX1, CRKL, MAPK1 DiGeorge probe	[ch22:19068456-19932689/21096895-21454102/21096895-21454102]
		22q11.2/22q13	HIRA/ARSA (By clinical request only)	[chr22:19289001-19405903] ¹
KALLMANN SYNDROME	7*	Xp22.3/Xp11.1-q11.1	KAL1/CEP X	[chrX:8546313-8679945] ¹
		Xp22.3/Xp22.3/Xp11.1-q11.1	STS/KAL1/CEP X	
KLINEFELTER SYNDROME	2	Xp11.1-q11.1/Yp11.1-	CEP X/Y/(18)	² Not mapped to the human genome.
		q11.1/(18p11.1-q11.1)		
MILLER-DIEKER SYNDROME (17p13.3) critical region=LIS1	7*	17p13.1	RAI/LIS1	[chr17: 2,480,407-2,597,775] ³
NEWBORN SEX DETERMINATION/AMBIGUOUS GENITALIA	2	Xp11.1-q11.1/Yp11.1-q11.1	CEP X/Y(18) (or CEP X/Y)	² Not mapped to the human genome.
		q11.1/(18p11.1-q11.1)		
		Yp11.3/Xp11.1-q11.1	SRY/CEP X	
PALLISTER-KILLIAN SYNDROME *	7*	12p12/cep12	12p12(EG)/CEP12	
POI/SRY DELETION/SEX REFERRAL/TURNER SYNDROME - use both probes	2	Yp11.3/Xp11.1-q11.1	SRY/CEP X	[chrY:2647360-2769346] ¹
		Xp11.1-q11.1/Yp11.1-q11.1/	CEP X/Y(18) (or CEP X/Y)	² Not mapped to the human genome.
		(18p11.1-q11.1) (or Xp11.1-q11.1/Yq12)		
PRADER WILLI/ANGELMAN SYNDROME	7*	15q11.2/15p11.2/15q24	SNRPN/CEP 15(D15Z1)/PML	
		15q11.2/15p11.2/15q25	D15S10/CEP 15(D15Z1)/PML	
RETINOBLASTOMA	7*	13q14	RB1	[chr13:48859964-49061601] ¹
		13q14/13q12	RB1/D13S1574/SHGC-141583	
SMITH-MAGENIS SYNDROME (17p11.2 critical region=RAI1)	7*	17p11.2	RAI/LIS1	[chr17: 17,645,577-17,805,444] ³
SHORT STATURE	2	Xp22.3/Xp11.1-q11.1/	SHOXa/CEPX(DXZ1)/SHOXb/CEPY(DYZ1)	
		Yp11.3/Yq12		[chrX: 562,246-699,558] ³
TRISOMY 21 (DOWN SYNDROME)	2	13q14/21q13-q22.2	13 RB1 /21 DSCR4 unique sequence	[chr13:48735473-49158073 /chr21:39439949-39439949]
TRISOMY 18 (EDWARDS SYNDROME)	2	Xp11.1-q11.1/Yp11.1-	CEP X/Y/18	² Not mapped to the human genome.

FISH PROBE LIST

TRISOMY 18 (EDWARDS SYNDROME)		q11.1/18p11.1-q11.1	CEP 4 / 17 / 18	
TRISOMY 13 (PATAU SYNDROME)	2	13q12.11/21q22.13-q22.2	13 RB1 /21 DSCR4 unique sequence	[chr13:48735473-49158073 /chr21:39439949-39439949]
WILLIAMS-BEUREN SYNDROME	7*	7q11.23/7q31	ELN/D7S486,D7S522	[chr7:73428837-73643684 /chr7:115675366-11675366]
WOLF-HIRSCHHORN SYNDROME	7*	4p16.3/4p11-q11	WHCR/CEP 4	[chr4:19471111-2044724] ¹
HAEMATOLOGY FISH TESTING		Probe Location	Probe	
ALL Panel (Paed B-ALL)	2*	12p13/21q22	ETV6/RUNX1	
		11q23	MLL (KMT2A) BA	
		22q11.2/9q34	BCR/ABL1 DF/DC	
		4p11-q11/10p11.1-q11.1*	CEP4 /CEP10	*required if COG patient or evidence of Hyperdiploidy
Adult B-ALL	2*	22q11.2/9q34	BCR/ABL1 DF/DC	
ALL High risk panel (COG HR cases only)/Ph-like B-ALL (unvalidated -individual probes as required)	7*	9q34	ABL1 BA	
		1q25.2	ABL2 BA	
		Xp22.33/Yp11.32	CRLF2 BA	
		19p13.2	EPOR BA (REQUESTED)	
		5q32	CSF1R BA (REQUESTED)	
		9p24.1	JAK2 BA(REQUESTED)	
		4q12	FIP1L1-CHIC2-PDGFR A BA	
		5q32	PDGFRB BA	
ALL (ADULT/T-CELL)	7*	22q11.2/9q34	BCR/ABL1 DF/DC	
AML MyeChild panel - For use when G-banding is negative for expected abnormalities	7*	9q34	ABL1 BA	
		11q23	MLL (KMT2A) BA	
		12p13	ETV6 BA	
		inv(16)(p13.3q24.3)	CBFA2T3/GLIS2	
		t(5;11)(q35;p15.4)	NUP98 BA	
AML (MyeChild probes) for confirmation of abnormalities found on G-banding (individual probes as required)	7*	16q22	CBFB BA	
		8q22/21q22	RUNX1/RUNX1T1 DF	
		3q	MECOM BA	
		t(6;9)	DEK NUP 214 DF	
		22q11.2/9q34	BCR/ABL1 DF/DC	
		t(3;21)(q26;q22)	MECOM/RUNX1	
		t(4;11)(q21;q23)	AFF1/KMT2A	
		t(6;11)(q27;q23)	AFDN/KMT2A	
		t(11;19)(q23;p13.3)	KMT2A/MLLT1	
AML MyeChild- if NUP98 BA is abnormal	7*	t(5;11)(q35;p15.4)	NSD1/NUP9	
AML MyeChild- if ETV6 BA is abnormal	7*	t(7;12)	MNX1-ETV6	
APML	1	15q24/17q21.1-q21.2	PML/RARA DF	
		17q21	RARA BA (if variant) -By clinical request only	
CHIMERISM	2	Xp11.1-q11.1/Yp11.1-q11.1/	CEP X/Y(18)	

FISH PROBE LIST

CLL Panel (suspension samples only)	7*	(18p11.1-q11.1)	CEP 12 (12)	
		11q22.3/17p13.1	ATM/TP53	
		13q14.3/13q34/12p11.1-q11	D13S319/LAMP1/CEP 12 (D12Z3)	
CML	2*	22q11.2/9q34	BCR/ABL1 DF/DC	
		22q11.2/9q34	BCR/ABL1 ES (By clinical request only)	
		22q11.2/9q34	BCR/ABL1,ASS1 (By clinical request only)	
MPN AND MDS (individual probes as required)	7*	7q31/7p11.1-q11.1	D7S522/CEP7	
		5q31/5p15.2	EGR1/D5S23,D5S721	
		5q32-33.1	PDGFRB BA	
		8q21.3/21q22	RUNX1/RUNX1T1 DF	
		15q24/17q21.1-q21.2	PML/RARA DF	
		16q22	CBFB BA	
		4q12	FIP1L1-CHIC2-PDGFR BA	
		8p11	FGFR1 BA	
MYELOMA Panel (suspension samples only)	7*	11q22.3/17p13.1	ATM/TP53	
		13q14.3/13q34/12p11.1-q11	D13S319/LAMP1/CEP 12 (D12Z3)	
		1q21.2/1p32.3	CKS1B/CDKN2C	
		14q32.3	IGH BA	
MYELOMA - if IGH abnormal, 1st line probes		14q32.3/4p16.3	IGH/FGFR3 (If IGH abnormal)	
		14q32.3/11q13.3	IGH/CCND1 XT (If IGH abnormal)	
MYELOMA - if IGH abnormal and 1st line probes normal		t(14;16)(q32;q23)	IGH/MAF DF[V] (If 1st line probes normal)	
		t(14;20)(q32;q12)	IGH/MAFB DF[M] (If 1st line probes normal)	
LYMPHOMAS		Probe Location	Probe	
ANAPLASTIC LARGE CELL LYMPHOMA (ALCL)	18	2p23	ALK BA	
ALK1-NEG ANAPLASTIC LARGE CELL LYMPHOMA (ALCL)	18	6p25.3	IRF4, DUSP22	
BURKITT LYMPHOMA	18	8q24	MYC BA	
		8q24.21/14q32.3	MYC/IGH	
		t(2;8)(p11;q24)	IGK/MYC (By clinical request only)	
		t(8;22)(q24;q11)	IGL/MYC (By clinical request only)	
		t(2;8)(p11;q24)	IGK BA (By clinical request only)	
		t(8;22)(q24;q11)	IGL BA (By clinical request only)	
HIGH GRADE B-CELL LYMPHOMA WITH 11q ABERRATION (PREVIOUSLY BURKITT-LIKE)	18	8q24	MYC BA	
		8q24.21/14q32.3	MYC/IGH	
		t(2;8)(p11;q24)	IGK/MYC DF(By clinical request only)	
		t(8;22)(q24;q11)	IGL/MYC (By clinical request only)	
		t(2;8)(p11;q24)	IGK BA (By clinical request only)	
		t(8;22)(q24;q11)	IGL BA (By clinical request only)	
		11q23.3 /11p11.1-q11 [mix KMT2A BA with C	KMT2A(V)/CEP1	
		11pter/11qter	Mix11	
DIFFUSE LARGE B-CELL LYMPHOMA (DLCL)/DOUBLE or TRIPLE HIT		8q24	MYC BA	

FISH PROBE LIST

DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)/DOUBLE OF TRIPLE HIT LYMPHOMAS	18	8q24.21/14q32.3	MYC/IGH	
		18q21	BCL2 BA	
		3q27	BCL6 BA	
		t(2;8)(p11;q24)	IGK/MYC (By clinical request only)	
		t(8;22)(q24;q11)	IGL/MYC (By clinical request only)	
		6p25.3	IRF4, DUSP22 (By clinical request only)	
FOLLICULAR LYMPHOMA	18	14q32.3/18q21.3	IGH/BCL2 DF	
		18q21.3	BCL2 BA (By clinical request only)	
LARGE B CELL LYMPHOMA WITH IRF4 REARRANGEMENT	18	6p25.3	IRF4, DUSP22	
MANTLE CELL LYMPHOMA	18	14q32.3/11q13.3	IGH/CCND1 DF	
		11q13	CCND1 BA (By clinical request only)	
MALT CELL LYMPHOMA/ MARGINAL ZONE LYMPHOMA	18	18q21	MALT1 BA	
		t(11;18)(q22.2;q21.32)	MALT1/BIRC3(API2) (By clinical request only)	
		14q32.3	IGH BA (By clinical request only)	
		1p22	BCL10 BA (By clinical request only)	
NON-HODGKINS LYMPHOMA (probes as required)	18	14q32.3	IGH BA	
		3q27	BCL6 BA	
		18q21	BCL2 BA	
		8q24	MYC BA	
		8q24.21/14q32.3	MYC/IGH	
		18q21.3	MALT1 BA	
		2p23	ALK BA	
		14q32.3/11q13.3	IGH/CCND1 DF	
PLASMACYTOMA (NOT VALIDATED)	18	11q22.3/17p13.1	ATM/TP53	
		13q14.3/13q34/12p11/1-q11	D13S319/LAMP1/CEP 12 (D12Z3)	
		14q32.3	IGH BA	
		1q21.2/1p32.3	CKS1B/CDKN2C	
SLL (NOT VALIDATED)	18	11q22.3/17p13.1	ATM/TP53	
		13q14.3/13q34/12p11.1-q11	D13S319/LAMP1/CEP 12 (D12Z3)	
T-PROLYMPHOCYTIC LEUKEMIA (T-PLL) (NOT VALIDATED)	18	14q11.2	TRA/D breakapart probe	
LEUKEMIA CUTIS (NOT VALIDATED)	18	Trisomy 8	MYC/IGH/CEP 8	
SOLID TUMORS		Probe Location	Probe	
ADENOCARCINOMA /NON SMALL CELL LUNG CANCER	5*	2p23	ALK BA	
		2p21	EML4 BA (By clinical request only)	
		2p23/2p21	ALK/EML4 (By clinical request only)	
		6q22	ROS1 BA	

FISH PROBE LIST

		7q31.2/7p11.1-q11.1	MET/CEP7 (By clinical request only)	
ADENOID CYSTIC CARCINOMA	18	6q23.2-23.3	MYB BA	
ALVEOLAR SOFT PART SARCOMA (ASPS)	18	Xp11.23	TFE3 BA	
ANEURYSMAL BONE CYSTS/NODULAR FASCIITIS	18	17p13.2	USP6 BA	
ANGIOSARCOMA vs ATYPICAL VASCULAR LESION	18	8q24.2/8p11.1-8q11.1	MYC/CEP8(D8Z1)	
BILIARY MALIGNANCY/UROTHELIAL/BLADDER CANCER (carcinoma in situ/TCC)	18	3p11.1-q11.1/7p11.1-q11.1/ 17p11.1-q11.1/9p21.3	SE3/SE7/SE17(A)/p16	
BREAST CANCER	5*	17q12-q21.1/17p11.1-q11.1	ERBB2/CEP 17	
CLEAR CELL SARCOMA	18	22q12	EWSR1 BA	
CONGENITAL INFANTILE FIBROSARCOMA (UNVALIDATED)	18	1q23.1	NTRK1 BA	Can also occur in a number of other cancers
		9q21.32-q21.33	NTRK2 BA	Can also occur in a number of other cancers
		15q25.3	NTRK3 BA	Can also occur in a number of other cancers
CONGENITAL MESOBLASTIC NEPHROMA	18	12p13	ETV6 BA	
		5q31/5p15.2	EGR1/D5S23,D5S721	
DERMATOFIBROSARCOMA PROTUBERANS (DFSP)	18	22q13.1	PDGFB BA	
ENDOMETRIAL CANCER		17q12-q21.1/17p11.1-q11.1	ERBB2/CEP 17	
EPENDYMOMA-1q25 Gain*	18	1p36/1q25	1p36/1q25	See glioma canned comment
EWINGS SARCOMA / pNET	18	22q12	EWSR1 BA	
		16p11	FUS BA (By clinical request only)	
		21q22	ERG BA (By clinical request only)	
EWINGS NEGATIVE SARCOMA /PAED SARCOMA NOS (UNVALIDATED)	18	19q13.2	CIC BA (By clinical request only)	
		Xp11.4	BCOR BA (By clinical request only)	
		21q22	ERG BA (By clinical request only)	
EXTRASKELETAL MYXOID CHONDROSARCOMA	18	9q22.33-q31.1	NR4A3 BA	
		22q12-q13	EWSR1 (EWS) BA	
GASTRIC CANCER	5*	17q12-q21.1/17p11.1-q11.1	ERBB2/CEP 17	
GLIOMAS (individual probes as required)	5*	1p36/1q25	1p36/1q25	
		19p13/19q13	19p13/19q13	
		7p12/7p11.1-q11.1	EGFR/CEP 7	
		10q23/10p11.1-q11.1	PTEN/CEP 10	
		9p21/cen9	CDKN2A/CEP 9	
GLIOMA - PILOCYTIC ASTROCYTOMAS	5*	7p34	BRAF BA	
INFANTILE FIBROSARCOMA	18	12p13	ETV6 BA	
INFLAMMATORY MYOFIBROBLASTIC TUMOUR (IMT)	18	2p23	ALK BA	
LIPOBLASTOMA/CARCINOMA EX PLEOMORPHIC ADENOMA	18	8q21	PLAG1 BA	
LIPOMA (PLEOMORPHIC/SPINDLE CELL)	18	13q14.3/13q12.11	D13S319/CEP 13	
		16q13/16q11.2	RP11-325K04 / CEP16 (D16Z3)	
LIPOSARCOMA (ATYPICAL LIPOMATOUS TUMOUR (ATL) / DE-DIFFERENTIATED /WELL-DIFFERENTIATED)	18	12q15	MDM2/CEP 12	
		12q13	CDK4/CEP12	
LOW GRADE FIBROMYXOID SARCOMA (LGFMS)	18	16p11	FUS BA	

FISH PROBE LIST

MAMMARY ANALOGUE SECRETORY CARCINOMA	18	12p13	ETV6 BA	
MEDULLOBLASTOMA	5*	2p24/2p11.1-q11.1	MYCN/CEP 2	
		8q24.2/14q32.3/8p11.1-8q11.1	MYC/IGH/CEP8 (D8Z1)	
		17q22/17p13.1/17p11.1-q11.1	MPO/TP53/CEP 17	
MELANOMA OF SKIN	18	6p11.1-q11.1/6p25/6q23/11q13	CEP6/RREB1/MYB/CCND1	
		9p21.3/9p11.1-q11.1	CDKN2A/CEP9	
		8q24.2/8p11.1-8q11.1	MYC/CEP8(D8Z1)	
MESOTHELIOMA	18	9p21.3/9p11.1-q11.1	CDKN2A/CEP 9	
MYXOID / ROUND CELL LIPOSARCOMA	18	12q13	DDIT3 BA	
		16p11	FUS BA	
NEUROBLASTOMA	5*	2p24/2p11.1-q11.1	MYCN/CEP 2	
		1p36/1CEN	1p36/CCP1	
		11q22.3/11p11.1-q11.1	ATM /CEP 11	
NEUROFIBROMATOSIS TYPE 1 (NOT VALIDATED)	18	17q11.2/17pter	NF1/17pter	
NUT MIDLINE CARCINOMA	18	15q14	NUTM1 BA	
RENAL CARCINOMA- CLEAR CELL SUBTYPE	18	3p14/3p11.1-q11.1	FHIT/CEP3	
		3p25/3p11.1-q11.1	VHL/CEP3	
		3p21	3p21 BAC probe	
RENAL CELL CARCINOMA- PAPILLARY SUBTYPE	18	7p11.1-q11.1/17p11.1-q11.1	CEP 7/CEP 17	
		Xp11.1-q11.1/Yq12	CEP X/Y	
RENAL CELL CARCINOMA with TFE3 REARRANGEMENT	18	Xp11.23	TFE3 BA	
RENAL CELL CARCINOMA -ONCOCYTOMA	18	CEP14/14qTER	CEP14 [S]/14qTER	
		CEP X/Y	CEP X/CEP Y (Yq12)	
		1p36(O)/1q25(G)	1p36/1q25	
RENAL CELL CARCINOMA - CHROMOPHOBE	18	2p24/cen2	MYCN/CEP 2	
		CEP6/CEP10/CEP17	CEP6 (G)/CEP10/CEP17	
RHABDOMYOSARCOMA (Alveolar subtype/ARMS)	18	13q14.11	FOXO1 BA	
		2q36.1/13q14.11	PAX3/FOXO1 SF	
		1p36.13/13q14.11	PAX7/FOXO1 SF	
SPINAL EPENDYMOMA (NOT VALIDATED)	18	2p24/cen2	MYCN/CEP 2	
SYNOVIAL SARCOMA	18	18q11.2	SS18 BA	
TERATOMA (GCT)*	18	12p12/cep12	12p12(EG)/CEP12	
UVEAL MELANOMA	18	3p14/3p11.1-q11.1	FHIT/CEP3	
		8q24.2/8p11.1-8q11.1	MYC/CEP8(D8Z1)	
		6p25/6q23/6p11.1-q11	RREB1 / MYB/ CEP 6 /CCND1 (By clinical request only)	

*All listed TATs are given as a guide only. NPAAC guidelines allow a TAT of 18 calendar days.
BA - Break apart probe, DF - Dual fusion probe, DC - Dual colour, SF - Single fusion probe
¹ February 2009 version of the UCSC Human Genome map.
²Centromeric probes contain highly repetitive sequence and locations do not map to the human genome.

FISH PROBE LIST

³GRCh37 version of the UCSC Human Genome map.

Uncontrolled copy
Current as of 22/04/2026 8:59